{"id":13179,"date":"2022-10-13T00:30:11","date_gmt":"2022-10-12T22:30:11","guid":{"rendered":"https:\/\/world-heart-federation.org\/?post_type=news&p=13179"},"modified":"2023-07-28T09:49:43","modified_gmt":"2023-07-28T07:49:43","slug":"the-polypill-could-avoid-millions-of-premature-deaths-heart-attacks-and-strokes-every-year-say-leading-cardiology-experts","status":"publish","type":"news","link":"https:\/\/world-heart-federation.org\/news\/the-polypill-could-avoid-millions-of-premature-deaths-heart-attacks-and-strokes-every-year-say-leading-cardiology-experts\/","title":{"rendered":"The polypill could avoid millions of premature deaths, heart attacks and strokes every year, say leading cardiology experts"},"content":{"rendered":"
Global health has paid a deadly price for not using simple, low-cost blood pressure lowering drugs, statins and aspirin widely in the form of a single pill, also known as the polypill. Widespread availability of polypills would substantially reduce the risk of cardiovascular disease (CVD) and be affordable for most people globally, says a call-to-action<\/a> by two leading cardiologists published today in The Lancet<\/em>.<\/p>\n \u201cDespite substantial scientific evidence of the high effectiveness, safety and affordability of the polypill, few such combined products are available, and in the few countries where they are available, use is low,” says Prof Fausto Pinto, President of the World Heart Federation.<\/p>\n \u201cThis systemic failure is a global tragedy, as many premature deaths from CVD could be avoided,\u201d says Prof Salim Yusuf, Executive Director of the Population Health Research Institute (PHRI) and Professor Emeritus of Medicine at McMaster University.<\/p>\n About 54 million people suffer from cardiovascular disease every year \u2013 a third of them die from CVD \u2013 with 80 percent of them living in low-income and middle-income countries.<\/p>\n The majority of heart attacks and strokes afflict people who have no prior CVD, meaning that (primary) prevention of the first heart attack or stroke is essential. Secondary prevention for people who already have CVD is also important but does not have the same impact.<\/p>\n “The current strategy for primary and secondary prevention of CVD has only been modestly successful in most countries, including high-income countries. Even in these countries, fewer than half of patients with prior CVD, and fewer than 20% without prior CVD, receive effective preventive treatments,\u201d says Prof Yusuf.<\/p>\n The polypill, also known as fixed-dose combination (FDC) therapy \u2013 with the combination of blood pressure lowering agents, a statin for lowering LDL cholesterol, and low-dose aspirin \u2013 was proposed\u00a0 in the early 2000s as a means to reduce CVD substantially and at low cost.<\/p>\n \u201cThe answer is now clear and resounding, with data from three independent, large, and long-term trials in primary prevention and one in secondary prevention showing its life-saving significance,” says Yusuf, whose various publications have\u00a0 shown that heart attacks and strokes were cut by 35 to 50 percent through the use of a polypill.<\/p>\n \u201cIt is time to use the polypill widely to save millions of lives each year,\u201d says Prof Pinto. He and Prof Yusuf recommend the following new strategies:<\/p>\n Global health has paid a deadly price for not using simple, low-cost blood pressure lowering drugs, statins and aspirin widely in the form of a single pill, also known as the polypill. Widespread availability of polypills would substantially reduce the risk of cardiovascular disease (CVD) and be affordable for most people globally, says a call-to-action […]<\/p>\n","protected":false},"featured_media":13180,"template":"","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"event":[],"project-campaign":[],"topic":[339],"class_list":["post-13179","news","type-news","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n\n
Download the press release:
\n<\/strong>Chinese<\/a>
\nEnglish<\/a>
\nFrench<\/a>
\nGerman<\/a>
\nSpanish<\/a>
\nPortuguese<\/a><\/h5>\n","protected":false},"excerpt":{"rendered":"